ZUG, Switzerland and CAMBRIDGE, Mass. , Sept. 20, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq:CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, today announced the pricing of an underwritten public offering of 4,210,526

ZUG, Switzerland and CAMBRIDGE, Mass. , Sept. 19, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq:CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, today announced that it is commencing an underwritten public offering of

- Aims to develop an immune-evasive stem cell therapy as a potentially curative treatment for diabetes - ViaCyte, Inc. Logo - Parties will collaborate through commercialization and share costs and profits worldwide - ZUG, Switzerland and CAMBRIDGE, Mass. and SAN DIEGO, Sept.

The interference proceeding remains terminated without any determination on inventorship of CRISPR/Cas9 genome editing application to eukaryotic cells   University of California/University of Vienna /Dr. Charpentier have patent applications covering the use of CRISPR/Cas9 genome editing technology

ZUG, Switzerland and CAMBRIDGE, Mass. , Aug. 30, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to make

-Obtained Approvals of CTAs in Multiple Countries for CTX001 in β-thalassemia and SCD- -Initiation of Clinical Trials for CTX001 in β-thalassemia and SCD on Track for 2018- -Preclinical Studies for CTX110 Targeting CD19+ Malignancies Have Begun- -Significantly Expanded Patent Portfolio with New

Patent granted for groundbreaking work by Jennifer Doudna's and Emmanuelle Charpentier's research teams in CRISPR/Cas9 genome editing technology Patent covers use of optimized guide RNA molecules ZUG, Switzerland and CAMBRIDGE, Mass. and BERKELEY, Calif., June 19, 2018 (GLOBE NEWSWIRE) -- CRISPR

ZUG, Switzerland and CAMBRIDGE, Mass. , June 05, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to present

BOSTON and ZUG, Switzerland and CAMBRIDGE, Mass. , May 30, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP) and Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that the U.S. Food and Drug Administration ( FDA ) has placed a clinical hold on the Investigational New Drug

ZUG, Switzerland and CAMBRIDGE, Mass. , May 15, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of the CRISPR team will make a series of presentations

-On track to begin CTX001 clinical study in hemoglobinopathies in 2018- -On track to file IND in 2018 for CTX101, allogeneic CRISPR-based CAR-T targeted toward CD19+ malignancies- - $341.8 million in cash as of March 31, 2018 - ZUG, Switzerland and CAMBRIDGE, Mass.

ZUG, Switzerland and CAMBRIDGE, Mass., May 03, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics  (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to present

-Off-the-shelf CAR-T candidates against BCMA and CD70 address both hematologic malignancies and solid tumors - -New data demonstrate high editing rates, consistent expression, selective and potent cell killing- ZUG, Switzerland and CAMBRIDGE, Mass., April 16, 2018 (GLOBE NEWSWIRE) -- CRISPR

ZUG, Switzerland and CAMBRIDGE, Mass. , April 13, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that the Company is scheduled to present new data on its allogeneic

ZUG, Switzerland and CAMBRIDGE, MA. , April 04, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, announced the appointment of Steve Caffé, M.D., as Head of Regulatory Affairs. Dr.

ZUG, Switzerland and CAMBRIDGE, Mass. , March 26, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, today announced the retirement of Dr.

- On track to begin first company-sponsored clinical trials of a CRISPR-based therapy - - Wholly-owned CRISPR-based allogeneic CAR-T programs advancing rapidly - ZUG, Switzerland and CAMBRIDGE, Mass. , March 08, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company

ZUG, Switzerland and CAMBRIDGE, Mass., Feb. 21, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics  (NASDAQ:CRSP), a genome editing company focused on creating transformative medicine for serious diseases, today announced that members of its senior management team are scheduled to present at four

ZUG, Switzerland and CAMBRIDGE, Mass. , Feb. 08, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq:CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, today announced that Bill Lundberg , MD, is stepping down as Chief Scientific

ZUG, Switzerland and CAMBRIDGE, Mass. , Jan. 04, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq:CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, today announced the pricing of an underwritten public offering of 5,000,000 of its

ZUG, Switzerland and CAMBRIDGE, Mass. , Jan. 03, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq:CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, today announced that it is commencing an underwritten public offering of